| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Statins and sepsis
1 Academic Department of Anaesthesia, Critical Care, and Pain, Heart of England NHS Foundation Trust, University of Warwick, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham B9 5SS, UK
2 Division of Medical Sciences University of Birmingham, Birmingham, UK
3 Lung Injury and Fibrosis Treatment Programme, University of Birmingham, Birmingham, UK
* Corresponding author. E-mail: f.g.smith{at}bham.ac.uk
 |
Abstract |
|---|
Top
Abstract
The importance of sepsisSevere sepsis and septic shock is common and frequently fatal. Over the last few years, the primary treatments demonstrated to improve outcome from several major clinical trials have finally emerged. However, translating these recent therapeutic advances to routine clinical practice has proven controversial, and new approaches of additional strategies are continued to be developed. Given their pleiotropic effects related to many pathophysiological determinants of sepsis, statin therapy could be the next step in the search for adjuvant therapy. A future challenge may be to test both the efficacy and the safety by large randomized controlled clinical trials ascertaining the effects of statins administered at the onset of sepsis and in patients with severe sepsis or septic shock admitted into intensive care units.
Keywords: complications, sepsis; infection; immune response; pharmacology, statins
|
The importance of sepsis |
|---|
The pathophysiological process of sepsis is a disease continuum from infection, signs and symptoms of infection (SSI, used to be termed as systemic inflammatory response syndrome SIRS), sepsis, severe sepsis, and multi-organ dysfunction.54 71 Internationally recognized definitions are outlined in Table 1.
|
Severe sepsis is common, the prevalence being approximately 2.3 cases per 100 hospital discharges in the USA, which translates into an annual burden of approximately 751 000 cases, and 68% of them require intensive care unit (ICU) treatment.12 The prevalence of severe sepsis in the first 24 h was estimated to be 27.1% in adult ICU in England, Wales, and Northern Ireland.93 Severe sepsis is frequently fatal, hospital mortality rate remains between 30% and 50%, or 500 000 deaths per year (1400 each day) worldwide, with as many deaths annually as those from acute myocardial infarction and the number is projected to grow at a rate of 1.5% per year.3
As the mortality rate of severe sepsis remains unacceptably poor, much research has been involved in the search for therapeutic interventions to improve outcomes. Over the last few years, several major clinical trials have finally shown that it is possible to reduce mortality in patients with sepsis.13 16 104 119 However, translating these recent therapeutic advances to routine clinical practice has proven controversial.15 82 Therapeutic interventions for management of severe sepsis and septic shock present a significant clinical challenge and new approaches and additional strategies continue to be developed. This review aims to assess the evidence of whether future treatment of sepsis would benefit from including statin therapy.
|
Pathophysiology of sepsis |
|---|
Opinions on the causes and potential therapies for sepsis have evolved significantly over the last 20 years. Mounting evidence suggests that beside well-established factors, such as virulence of pathogens or site of infection, individual differences in disease manifestation are a result of the genetic predisposition of the patient with sepsis.126
In this review, we have concentrated upon those aspects of the basic mechanisms of the septic process that are particularly relevant to statin therapy.
Cytokine cascade: too much of a good thing?
The inflammatory response is a central component of sepsis as it drives the physiological alterations that are recognized as the SIRS.100 A successful inflammatory response eliminates the invading microorganisms without causing lasting damage. Sepsis develops when the initial, appropriate host response to an infection becomes amplified, and then aberrant. Bacterial components reacting with specific toll receptors are believed to trigger monocytes, neutrophils, and endothelial cells (EC) to initiate an inflammatory cascade70 (Fig. 1).
|
Many believe that sepsis develops as a result of exuberant production of proinflammatory molecules such as TNF-
and IL-1, IL-6, and IL-8, lysosomal enzymes, superoxide-derived free radicals, vasoactive substances, such as platelet-activating factor (PAF), tissue factor (TF), and plasminogen activator inhibitor-1 (PAI-1).10 This occurs in conjunction with increases in the expression of inducible nitric oxide (NO) synthase, increasing production of NO resulting in coagulopathy, endothelial dysfunction, vascular instability, and eventually to apoptosis (i.e. programmed cell death) and multi-organ failure. Unfortunately, despite clinical trials of agents blocking single mediators, for example, TNF- and IL-1 results have been disappointing. However, a meta-analysis of studies of all TNF inhibitors did demonstrate overall improvement.77 Given the complexity of sepsis syndrome, merely blocking a single component may be insufficient to arrest the inflammatory process.43 Consideration needs to be given to modulation of multiple targets which are central to the pathophysiological response in sepsis. Where activation of a critical part of the inflammatory pathway exhibits multiple or redundant pathways, we may need to intervene at two or more drivers of the process.107 Therefore, future strategies of intervention which modify several arms of the inflammatory cascade may possibly be more successful.82
Cytokine cascade: too little of a good thing?
In contrast to the hypothesis of exuberant inflammatory response in sepsis, is the finding that septic patients may have a relative anti-inflammatory environment. Thus, TNF:IL-10 ratios may be reduced, producing the equivalent of a blunted inflammatory response.117 Defective mediator production in response to stimuli has been seen in both monocytes and T lymphocytes.30 The blunted monocyte response seen in sepsis has been successfully reversed with interferon gamma and this proved effective in a small series of sepsis patients. However, a larger trial of trauma patients showed that although interferon gamma did reduce deaths due to infections, it did not reduce overall mortality.36
Vascular damage in sepsis
Recent attempts at a unifying hypothesis have been developed to explain the vascular changes in septic shock37 on the basis of the effect of inflammatory mediators on the vascular endothelium.28 57 The endothelium is involved in the control of vascular tone, vascular permeability, and coagulation,24 and a number of changes in it follow exposure of EC to relevant proinflammatory mediators.44 It has therefore been proposed that widespread endothelial damage and death occurs during human sepsis and leads to organ dysfunction and failure: the multi-organ dysfunction syndrome (MODS). This pan-endothelial damage is particularly important within the pulmonary circulation and results in high permeability pulmonary oedema that is clinically recognized as ARDS and necessitates mechanical ventilation.115
A role for endothelial apoptosis in sepsis?
Cellular death may be a key factor in sepsis and its related mortality. Cells that are destined to die can do so by two mechanisms: apoptosis and necrosis. The role of endothelial cell apoptosis in sepsis remains inconclusive due to the challenges involved in study of endothelial cell death in vivo. A major problem is that dying EC detach from the basement membrane and leave the vessel wall. Thus, apoptotic EC may not be detected on routine histology.50 Nevertheless, in humans soluble Fas levels are elevated in patients with multi-organ failure and levels fall during recovery.35 78 In addition, circulating levels of nuclear matrix protein, a general cell death index, is elevated in sepsis-related MODS patients and correlates with severity.127 Finally, circulating EC have been detected in the blood of patients with sepsis supporting a role of endothelial cell death in early sepsis.88
In sepsis, cytokine-induced coagulopathy triggers increased activity of TF and PAI-1 and decreased levels of the natural anticoagulant protein C on mononuclear and EC (Fig. 2).25 TF in turn activates a series of proteolytic cascades, which result in the conversion of prothrombin to thrombin, which in turn generates fibrin from fibrinogen. Simultaneously, PAI-1 prevents the conversion of plasminogen to plasmin, which results in impaired fibrinolysis. The activated form of protein C, aPC, formed when thrombin links with thrombomodulin (TM), inactivates factors Va and VIIa, and inhibits PAI-1 activity; hence, protein C deficiency results in further procoagulant effect. The net result is enhanced formation of fibrin clots in the microvasculature, leading to microvascular occlusion, impaired tissue perfusion, and then multi-organ failure.25
|
Recombinant activated protein C (drotrecogin alfa, rhAPC) is currently the only pharmacological intervention available with anti-thrombotic and profibrinolytic property to treat severe sepsis. But rhAPC is expensive, can only be administered i.v., and bleeding is a risk.16 In addition, efficacy of activated protein C has been called into question recently and further research is being done to confirm the previous findings.
|
The need for new treatments in sepsis |
|---|
Despite a considerable amount of research into the mechanisms of sepsis and investment in clinical trials of drugs that block single mediators, with the possible exception of activated protein C, no therapy targeting the inflammatory cascade has been shown to alter mortality in sepsis. Clearly, this represents a major healthcare need. The ideal agent would be cheap, have a clearly established and minimal side-effect profile, multiple modes of delivery, and have a pleiotropic effect upon the inflammatory cascade. We have assessed how close statins come to this ideal.
|
Pharmacology of statins |
|---|
The statins are a class of lipid-lowering drugs which inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (Fig. 3). HMG-CoA reductase catalyses the conversion of hydroxymethylglutaryl-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis, leading to cholesterol-lowering effects. In clinical studies, statins reduce total cholesterol, low-density lipid (LDL) cholesterol, apolipoprotein B, and triglyceride levels.
|
Seven drugs in the ‘statin’ class are now approved for clinical use in their hypolipidaemic effects in at least one country: lovastatin, pravastatin sodium, and simvastatin are fungal-derived inhibitors of HMG-CoA, whereas atorvastatin calcium, fluvastatin sodium, rosuvastatin, and pitavastatin are fully synthetic compounds.29 Cerivastatin sodium was withdrawn from the world market by the manufacturer in 2001 because of reports of fatal rhabdomyolysis.40 Six statins (not cerivastatin and pitavastatin) are currently used in the UK,1 17 although simvastatin and atorvastatin account for around 85% of all statin prescriptions in the UK.86
|
Rationale for statin use in sepsis: cell-based studies |
|---|
Over the preceding decade, HMG-CoA reductase inhibitors have emerged as potentially powerful inhibitors of the inflammatory process44 (Table 2). The mechanism by which statins modulate the immune response is complex, but is often regarded as lipid independent as they are not related to lowering LDL cholesterol. Nevertheless, these effects primarily involve the inhibition of isoprenoid lipid production and subsequent protein prenylation and activation of signalling proteins such as the small GTPases.45
|
Statins have also been shown to directly bind to the leucocyte integrin LFA-1 (also known as CD11a/CD18) and so interfere with its principal ligand ICAM-1.125 However, since most of the effects of statins can be reversed with mevalonate supplementation, it is likely that non-HMG-CoA reductase effects are not a major mechanism. The cell processes affected by statins are ubiquitous within humans and therefore affect the function of most cell types. Thus, their impact on inflammation involves modulation of leucocyte biology, altered antigen presenting cell function, and changes in epithelial and EC. It is these pleiotropic actions of statins that underlie their potential effectiveness as immunomodulators in sepsis.
Effect of statins on the leucocyte response in sepsis
Sepsis results in a significant and time-dependent increase in leucocyte recruitment, adherence, and transmigration of leucocytes and P-selectin expression on vascular endothelium. Statins greatly reduce both lipopolysaccharide (LPS)-induced and Staphylococcus aureus -toxin-induced leucocytes migration and leucocytes recruitment.33 99 105 Statins result in a significant reduction of leucocytes adhesion to endothelium by down-regulation of surface expression of endothelial cell adhesion molecule P-selectin, CD11b, and CD18 and by inhibition of lymphocyte function antigen-1 (LFA-1)-mediated leucocyte adhesion.99 124 129 131
Statins also affect monocyte functions. A double-blind, placebo-controlled study,89 randomized healthy volunteers to receive either simvastatin (80 mg day–1) or placebo for 4 days before i.v. LPS administration (20 IU kg–1), showed that simvastatin attenuated up-regulation of toll-like receptors (TLR) 4 and 2 on the surface of monocytes by more than half after LPS challenge (P<0.02). Suppressed TLR4 and TLR2 expression was associated with decreased circulating concentrations of TNF- and monocyte chemoattractant protein-1.
Effect of statins on the drivers of sepsis
Statins affect the production of many acute phase reactants, such as IL-6, IL-8, TNF-, monocyte chemoattractant protein-1 (MCP–1), and C-reactive protein (CRP).4 14 33 41 46 55 59 87 101–103 105 114 CRP is mainly produced by hepatocytes in response to IL-6. In an in vitro study,14 human hepatocytes were stimulated with IL-6 in the presence or absence of simvastatin and atorvastatin. Hepatocytes treated with statins showed significant inhibition of IL-6-induced CRP production. The reduction of CRP levels was more pronounced with atorvastatin than with other statins.14 58
Effect of statins on coagulation cascade
Statins improve platelet function and diminish procoagulant activity by a reduction in platelet aggregation, TF activity, reduced conversion of prothrombin to thrombin with resultant reduced thrombin activity, and a decline in levels of fibrinogen.5 26 49 52 62 79 90 112 Statins also seem to stimulate fibrinolysis by altering the level and activity of tissue plasminogen activator (tPA) and PAI-1.18 32 60 In vitro, atorvastatin strongly increased the expression and functional activity of TM in human umbilical vein EC and human coronary artery EC,110 indicating a potential role in the treatment of protein C deficiency. This raises the possibility that statins, particularly atorvastatin, could offer a potential pharmacological treatment for severe sepsis.
Effect of statins on endothelial cell function
As discussed above, the microvascular circulation and particularly endothelial cell dysfunction is central to the pathogenesis of sepsis, and this was reviewed in the British Journal of Anaesthesia last year.81 As sepsis develops, EC become activated, participating in the inflammatory process and generating multiple inflammatory mediators and up-regulating adhesion molecule expression. Endothelial cell adhesion molecules not only act as docking structures for leucocytes, but also activate the signalling cascades required for successful leucocyte transmigration. The weight of evidence suggests that statins inhibit this process.
A reduction in the activation of pro-inflammatory transcription factors in EC also represents a key mechanism by which statins exert their immunomodulatory effects. This appears to be due to reduced levels of NF-kappaB and so statins can block the effects of cytokines such as TNF- upon EC. These effects of statins on vascular endothelium have been closely associated with their ability to up-regulate endothelial NO synthase (eNOS) activity and enhance NO production.
Physiologically, eNOS is activated by the protein kinase Akt to produce endothelium-derived NO for controlling vasomotor activity.73 Sepsis results in a decrease in eNOS function and an increase in inducible NO synthase (iNOS) expression, contributing to the hypotension and resistance to vasopressor drugs that occur in septic shock.7 42 63 98 Statins increase eNOS activity by inducing Akt-mediated phosphorylation of eNOS,61 up-regulating eNOS expression,64–69 and activating eNOS directly.56 This may be anti-inflammatory locally on EC as NO prevents leucocyte chemotaxis and reduces endothelial adhesion molecule expression, which in turn attenuates leucocyte migration. Activation of the Akt pathway by statins may also be important as it leads to reduced endothelial cell apoptosis in vitro.
Statins have also been found to increase the number of circulating endothelial progenitor cells (EPCs).72 Indeed, statins induce angiogenesis by promoting the proliferation, migration, and survival of circulating EPC.122
|
Rationale for statin use in sepsis: animal studies |
|---|
Clearly, statins affect many pathways in vitro that are believed to be involved in the pathogenesis of sepsis. These pleiotropic actions, therefore, provide a rationale for their use in inflammatory diseases such as sepsis. However, the in vitro studies alone do not provide a clear rationale for clinical studies in humans. It is for this reason that consideration of animal studies is important.
Several animal models have been used to look at the effects of statin therapy in sepsis. In a LPS-induced sepsis murine model, pre-treatment with cerivastatin significantly improved 7-day survival. Pre-treatment with cerivastatin also reduced serum levels of TNF- and IL-1beta at 2 h and NO, nitrite, and nitrate at 8 h.9
In the mouse cecal ligation and puncture (CLP) model of polymicrobial sepsis, pre-treatment with simvastatin significantly increased both the rate of 3-day survival from 26% to 73%128 and duration of survival from 28 to 108 h85 compared with untreated mice. This improvement was associated with a preservation of cardiac function and haemodynamic status, which were severely impaired in untreated CLP mice. As one of the underlying mechanisms, the authors found increased mononuclear cell adhesiveness in septic mice, an important contributor to sepsis pathophysiology, to be reversed by statin treatment.85
A subsequent CLP study in mice demonstrated that this effect was seen with simvastatin, atorvastatin, and pravastatin but not with fluvastatin. Taken together, these studies provide significant animal model evidence to support the immunomodulatory effect of statins in sepsis and suggest that this is a class effect of statins.84
|
Evidence for anti-inflammatory effects of statins in vivo in humans |
|---|
A randomized controlled trial (RCT)74 demonstrated that patients with acute coronary syndrome treated with atorvastatin 40 mg day–1 had a rapid reduction in CRP (a mean of 4 days after initiation of treatment) compared with placebo. Atorvastatin 40 mg day–1 produced 32% more effect than equipotent doses of fluvastatin, lovastatin, provastatin, or simvastatin in reducing CRP levels in patients with coronary heart disease.
Systemic inflammatory response occurs frequently after coronary artery bypass surgery, and it is strongly correlated with the risk of postoperative morbidity and mortality. In a double-blinded, placebo-controlled, randomized study, atorvastatin (20 mg day–1) for 3 weeks before surgery significantly reduced IL-6 and IL-8 release and neutrophil adhesion to the venous endothelium in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass.20
In inflammatory conditions other than ischaemic heart disease, statins have been shown to improve disease activity. For example, the trial of atorvastatin (40 mg day–1) in 116 patients with active rheumatoid arthritis (TARA)80 demonstrated a significant improvement in clinical disease activity score. CRP and erythrocyte sedimentation rate declined by 50% and 28%, respectively, in the atorvastatin group compared with the placebo group. These studies, therefore, indicate that statins are effective in decreasing systemic and vascular inflammation in humans in vivo.
|
Rationale for statin use in sepsis: clinical studies |
|---|
The clinical studies that have described effects of statins in sepsis have either addressed the effects of statins in reducing sepsis incidence/severity or retrospectively looked at mortality in those taking statins who developed sepsis. Many of these studies have been elegantly reviewed by Chua and colleagues.21 We will concentrate upon the most recent studies (Table 3).
|
Does statin treatment reduce the incidence of infection in patients at risk of sepsis?
An examination of the UK General Practice Research Database to identify the risk of pneumonia in diabetic patients in relation to statin therapy118 found 4719 patients who developed pneumonia after starting statin therapy, and matched them with controls in a 1:3 ratio. Statin therapy reduced the risk. This effect persisted after adjustment for confounding and in sub-group analyses. A prospective observational study of 11 490 patients6 with atherosclerosis to assess death from infection, in which 50% of the patients were on statin therapy, found a mortality from infection of 0.9% in the statin patients compared with 4.1% in those not on statins. The relative risk of death from infection in statin patients was 0.22 (95% CI 0.17–0.28). Statin therapy remained beneficial after adjustment for confounding factors and propensity matching. A prospective study of the risk of hospital admission for sepsis in 1041 patients with chronic renal failure requiring dialysis47 found that 303 patients were hospitalized for sepsis. The risk of hospital admission for sepsis in statin users was 0.41 (95% CI 0.25–0.68), which was reduced further after adjustment for potential confounders and propensity matching for statin therapy. Similarly, a study using a large database combining data from several Healthcare Management Organizations39 examined the effect of statin therapy on death from influenza or COPD. Moderate dose statin therapy is defined as a dose
4 mg day–1 protected against death from pneumonia with an odds ratio of 0.49 (95% CI 0.26–0.76). In contrast, a recent study found that statins are not associated with reduced mortality or need for admission to an ICU in patients with pneumonia and reports of benefit in sepsis may be a result of confounding variables.75
Does statin therapy reduce the risk of developing severe sepsis?
In a prospective observational cohort study of 361 consecutive patients admitted with suspected or documented acute bacterial infection, severe sepsis developed in 19% of patients in the no pre-statin group compared with only 2.4% of the pre-statin group.8 More recently, a study48 using propensity-based matching, which accounted for each individual's likelihood of receiving a statin, yielded a cohort of 69 168 patients with cardiovascular disease, of whom half (n=34 584) received a statin and half (n=34 584) did not. They found that patients receiving statins had a 19–25% lower incidence of sepsis, severe sepsis, or fatal sepsis than those in controls [hazard ratio, HR (95% CI) 0.81 (0.72–0.91), 0.83 (0.70–0.97), and 0.75 (0.61–0.93), respectively].
Does statin therapy reduce mortality in sepsis?
A prospective observational study of 2036 patients with suspected infection attending the emergency department34 found that the 412 patients on statin therapy had a clinically and statistically significant reduction in mortality. Absolute mortality was 1.9% (95% CI 0.6–3.3%) in patients on statins when compared with 4.4% (95% CI 3.4–5.4%) in those not on statins. Multiple logistic regression was used to control for severity of illness and co-morbidities, and the odds ratio of death for statin patients was 0.44 (0.20–0.94, P=0.03). Schlienger and colleagues109 used the United Kingdom General Practice Research Database to identify 55 118 patients on statin therapy, and then match a subset of 1253 of these patients who developed pneumonia to controls in a 1:4 ratio. After adjustment for co-morbidity and frequency of visits to their physician, the authors found a large reduction in risk of fatal pneumonia with an odds ratio of 0.47 (95% CI 0.25–0.88).
Clinical studies summary
In summary, there is circumstantial evidence from retrospective database enquiries and observational studies that statins may be helpful in sepsis. However, these studies do not explain why the incidence of sepsis is increasing, despite raising the use of statins in the population and all of these studies have methodological flaws that mean they are poor surrogates for RCT.
|
Limitations of statins as a treatment for sepsis: side-effects |
|---|
The American College of Cardiology/American Heart Association/National Heart, Lung, and Blood Institute has issued a clinical advisory on the use and safety of statins.95 Statins have proven to be extremely safe in the vast majority of patients receiving them. Few significant side-effects were observed in clinical trials, and post-marketing reports of adverse events have been very limited when considered in comparison with the very large number receiving these drugs.95 Two common side-effects are, however, particularly relevant in sepsis: liver dysfunction and myositis. Many changes in liver function occur during the course of sepsis. At the onset of sepsis, the liver increases most of its functional capacities. However, within a few days, detoxification processes have been shown to deteriorate as a first sign of septic liver failure.92 The cytochrome P450 system is of particular interest in the context of statin therapy in sepsis since the cytochrome P450 (CYP) isoform CYP3A4 serves as the major pathway for metabolism of lovastatin, simvastatin, atorvastatin, and cerivastatin.
Statins can adversely affect hepatic function. Elevated hepatic transaminases occur in 0.5–2.0% and are dose-dependent.19 51 Transaminase elevation is frequently reversed with a reduction in dose, or selection of another statin.53 Statins have not been shown to worsen the outcome in persons with chronic transaminase elevations due to hepatitis B or C, and treatment of hyperlipidaemia may actually improve transaminase elevations in individuals with fatty liver.11 Nevertheless, in the context of severe sepsis, where hepatic dysfunction is common, the use of statins may be contraindicated in some patients.
Abnormal creatinine kinase levels are also commonly encountered in sepsis patients, particularly those with invasive streptococcal disease.31 This represents a problem for statin therapy in sepsis since the most serious adverse effect associated with statin therapy is myopathy, which may progress to severe myositis and rhabdomyolysis.
Non-specific muscle aches or joint pains that are generally not associated with significant increases in creatine kinase (CK) are a common complaint in clinical trials.95 In placebo-controlled cholesterol lowering trials, the incidence of these complaints, generally reported as about 5%, is similar between placebo and active drug therapy, suggesting that they may not be drug-related.11 19 27 38 53 96 However, occasionally patients treated with a statin exhibit severe myositis characterized by muscle symptoms with increased CK levels. Failure to discontinue drug therapy can lead to rhabdomyolysis, myoglobinuria, and acute renal necrosis.76 97 It is not known whether patients with sepsis are more prone to the muscle side-effects of statins and this would require large clinical trials to answer.
|
Limitations of statins as a treatment for sepsis: mode of delivery |
|---|
The current seven drugs in the ‘statin’ class are only available as an oral preparation. All statins are absorbed rapidly from gastrointestinal tract after administration, reaching peak plasma concentration within 4 h.23 94 116 The lack of an i.v. formulation or of a clear pharmacokinetic profile for statins in patients with sepsis would need to be addressed before their use could become widespread. As statins are highly protein bound, it is particularly important to define the influence of hypoalbuminaemia on statin bioavailability and toxicology.
|
The need for randomized trials of statins as an adjunctive therapy in sepsis |
|---|
There is evidence from cell-based studies, animal models of sepsis, and observational clinical studies that statin treatment could be beneficial in patients with sepsis. However, not all clinical studies to date show a positive outcome. Clearly, there is need for properly conducted randomized placebo controlled trials in this context.83 91 113 123
There are several such trials presenting progress. The ASEPSIS trial intends to address the question as to whether statin therapy in early sepsis can modulate the development of severe sepsis compared with placebo. This trial is due to finish in 2008. The Intensive Care Society UK Clinical Trial group is investigating the effect of 40 mg simvastatin or placebo in patients with severe sepsis on plasma concentration of IL-6. In Belfast, the HARP study (ISRCTN70127774 [controlled-trials.com] ) is investigating simvastatin safety and effect on important surrogate clinical outcomes in 80 adult patients with sepsis-related acute lung injury. In Mexico, trial NCT00357123 [ClinicalTrials.gov] is determining the effect of rosuvastatin on sepsis after abdominal surgery. Similarly, trial NCT00452608 [ClinicalTrials.gov] is looking at the effect of atorvastatin upon inflammatory biomarkers in severe sepsis. In Vienna, trial NCT00450840 [ClinicalTrials.gov] is looking at simvastatin and shock reversal, as defined by cessation of vasopressor support for more than 1 h. Unfortunately, all these trials are single centre studies that do not have mortality as the primary outcome variable.
|
Conclusions |
|---|
The available evidence suggests that, in the future, treatment of sepsis may benefit from including statin therapy. Given their pleiotropic effects related to many pathophysiological determinants of sepsis, statin therapy may be the next logical step in the search for adjuvant therapy. However, there have been no RCT of statins in sepsis, and large randomized controlled clinical trials with clinically relevant primary endpoints are desperately needed. It is imperative to test the efficacy and safety and the benefit/adverse effects of statins administered at the onset of sepsis, as well as in patients with severe sepsis or septic shock admitted into ICUs.
|
Footnotes |
|---|
Declaration of interest. Professor Gao is the Chief Investigator of RCT on ‘Statin therapy in early sepsis can modulate the development of severe sepsis compared to placebo’ (ASEPSIS trial). The trial received a pump-prime research grant from Pfizer. Professor Gao and Dr Thickett have received travelling sponsorships from pharmaceutical and industrial companies to attend national and international conferences. 
|
References |
|---|
1 Best treatment, clinical evidence for patients from the BMJ. (2006).
2 Search the Medscape Drug Reference. (2006).
3 2006) Available from http://www.ihi.org/IHI/Topics/CriticalCare/Sepsis/ (accessed July 2006).
4 Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 286:64–70.
5 Alfon J, Pueyo PC, Royo T, Badimon L. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost (1999) 81:822–7.[Web of Science][Medline]
6 Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med (2007) 35:372–8.[CrossRef][Web of Science][Medline]
7 Almog YM. Statins, inflammation, and sepsis: hypothesis [Editorial]. Chest (2003) 124:740–3.[CrossRef][Web of Science][Medline]
8 Almog YM, Shefer AM, Novack VM, et al. Prior statin therapy is associated with a decreased rate of severe sepsis [Article]. Circulation (2004) 110:880–5.
9 Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther (2000) 294:1043–6.
10 Andrews P, Azoulay E, Antonelli M, et al. Year in review in intensive care medicine, 2006. II Infections and sepsis, haemodynamics, elderly, invasive and noninvasive mechanical ventilation, weaning, ARDS. Intensive Care Med (2007) 33:214–29.[CrossRef][Web of Science][Medline]
11 Angulo P. Nonalcoholic fatty liver disease. N Engl J Med (2002) 346:1221–31.
12 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 29:1303–10.[CrossRef][Web of Science][Medline]
13 Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA (2002) 288:862–71.
14 Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 25:1231–6.
15 Bacon D, Forni LG. Recently published papers: Sugar, soap and statins—an unlikely recipe for the critically ill. Crit Care (2006) 10:140.[CrossRef][Medline]
16 Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 344:699–709.
17 British Medical Association RPSoGB BNF. 2.12 Lipid-regulating drugs. In: British National Formulary (2006) 51 Edn. London: BMJ Publishing Group Ltd and CRS Publishing.
18 Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol (2000) 20:556–62.
19 Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med (1991) 151:43–9.
20 Chello M, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med (2006) 34:660–7.[CrossRef][Web of Science][Medline]
21 Chua D, Tsang RS, Kuo IF. The role of statin therapy in sepsis. Ann Pharmacother (2007) 41:647–52.
22 Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther (2005) 78:342–50.[CrossRef][Web of Science][Medline]
23 Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol (1996) 36:604–9.[Abstract]
24 Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood (1998) 91:3527–61.
25 Cohen J. The immunopathogenesis of sepsis. Nature (2002) 420:885–91.[CrossRef][Medline]
26 Cortellaro M, Cofrancesco E, Arbustini E, et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost (2002) 88:41–7.[Web of Science][Medline]
27 Cressman MD, Hoogwerf BJ, Moodie DS, Olin JW, Weinstein CE. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia. Cleve Clin J Med (1988) 55:93–100.[Web of Science][Medline]
28 Curzen NP, Griffiths MJ, Evans TW. Role of the endothelium in modulating the vascular response to sepsis. Clin Sci (Lond) (1994) 86:359–74.[Medline]
29 Davidson MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs (2002) 11:125–41.[CrossRef][Web of Science][Medline]
30 de Werra I, Zanetti G, Jaccard C, et al. CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumonia. Swiss Med Wkly (2001) 131:35–40.[Medline]
31 Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991. Clin Infect Dis (1993) 16:792–800.[Web of Science][Medline]
32 Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells [Miscellaneous Article]. Arterioscler Thromb Vasc Biol (2003) 23:58–63.
33 Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol (2001) 21:1327–32.
34 Donnino M, Howell M, Cocchi M, Talmor D, Clardy P, Shapiro N. Statin therapy in patients with sepsis. Acad Emerg Med (2007) 14:S179.[CrossRef]
35 Doughty L, Clark RS, Kaplan SS, Sasser H, Carcillo J. sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome. Pediatr Res (2002) 52:922–7.[CrossRef][Web of Science][Medline]
36 Dries DJ, Jurkovich GJ, Maier RV, et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg (1994) 129:1031–41.
37 Evans TW, Smithies M. ABC of intensive care: organ dysfunction. Br Med J (1999) 318:1606–9.
38 Farmer JA. Learning from the cerivastatin experience. Lancet (2001) 358:1383–5.[CrossRef][Web of Science][Medline]
39 Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest (2007) 131:1006–12.[CrossRef][Web of Science][Medline]
40 Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med (2001) 2:205–7.[CrossRef][Web of Science][Medline]
41 Gattone M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. Ital Heart J Suppl (2001) 2:1133–4.[Medline]
42 Giusti-Paiva A, Martinez MR, Cestari Felix JV, et al. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats [Article]. Shock (2004) 21:271–5.[CrossRef][Web of Science][Medline]
43 Glauser MP. Pathophysiologic basis of sepsis: considerations for future strategies of intervention. Crit Care Med (2000) 28:S4–8.[CrossRef][Web of Science][Medline]
44 Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol (2007) 28:88–98.[CrossRef][Web of Science][Medline]
45 Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 6:358–70.[CrossRef][Web of Science][Medline]
46 Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res (2002) 51:58–62.[Web of Science][Medline]
47 Gupta R, Plantinga LC, Fink NE, et al. Statin use and hospitalization for sepsis in patients with chronic kidney disease. JAMA (2007) 297:1455–64.
48 Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet (2006) 367:413–8.[CrossRef][Web of Science][Medline]
49 Hale LP, Craver KT, Berrier AM, Sheffield MV, Case LD, Owen J. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol (1998) 18:1643–6.
50 Hotchkiss RS, Tinsley KW, Swanson PE, Karl IE. Endothelial cell apoptosis in sepsis. Crit Care Med (2002) 30:S225–8.[CrossRef][Web of Science][Medline]
51 Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother (1995) 29:743–59.[Abstract]
52 Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res (1999) 95:229–34.[CrossRef][Web of Science][Medline]
53 Hunninghake DB. Drug treatment of dyslipoproteinemia. Endocrinol Metab Clin North Am (1990) 19:345–60.[Web of Science][Medline]
54 IHI. Institute for Healthcare Improvement: Bundle up for Safety (2006) Available from http://www.ihi.org/IHI/Topics/Improvement/ (last accessed October 2006).
55 Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci (2000) 67:863–76.[CrossRef][Web of Science][Medline]
56 Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol (1999) 33:234–41.
57 Karima R, Matsumoto S, Higashi H, Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today (1999) 5:123–32.[CrossRef][Web of Science][Medline]
58 Kleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood (2004) 103:4188–94.
59 Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation (2000) 101:1760–3.
60 Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes [Review]. Drugs (2003) 63:1821–54.[CrossRef][Web of Science][Medline]
61 Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med (2000) 6:1004–10.[CrossRef][Web of Science][Medline]
62 Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation (1995) 92:3172–7.
63 Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med (2001) 345:588–95.
64 Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation (2000) 102:3104–10.
65 Laufs U, Endres M, Stagliano N, et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest (2000) 106:15–24.[Web of Science][Medline]
66 Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem (1997) 272:31725–9.
67 Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 31:2442–9.
68 Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation (1998) 97:1129–35.
69 Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 273:24266–71.
70 Leaver SK, Finney SJ, Burke-Gaffney A, Evans TW. Sepsis since the discovery of Toll-like receptors: disease concepts and therapeutic opportunities. Crit Care Med (2007) 35:1404–10.[CrossRef][Web of Science][Medline]
71 Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 29:530–8.[Medline]
72 Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest (2001) 108:399–405.[CrossRef][Web of Science][Medline]
73 Luo Z, Fujio Y, Kureishi Y, et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest (2000) 106:493–9.[Web of Science][Medline]
74 Macin SMM, Perna ERM, Farias EFM, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study [Article]. Am Heart J (2005) 149:451–7.[CrossRef][Web of Science][Medline]
75 Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. Br Med J (2006) 333:999.
76 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation (2000) 101:207–13.
77 Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov (2003) 2:391–405.[CrossRef][Web of Science][Medline]
78 Matute-Bello G, Liles WC, Steinberg KP, et al. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol (1999) 163:2217–25.
79 Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol (1992) 64:196–201.[CrossRef][Web of Science][Medline]
80 McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 363:2015–21.[CrossRef][Web of Science][Medline]
81 McGown CC, Brookes ZLS. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth (2007) 98:163–75.
82 Mekontso-Dessap A, Brun-Buisson C. Statins: the next step in adjuvant therapy for sepsis? Intensive Care Med (2006) 32:11–4.[CrossRef][Web of Science][Medline]
83 Merx MW, Weber C. Statins in the intensive care unit. Curr Opin Crit Care (2006) 12:309–14.[Web of Science][Medline]
84 Merx MWM, Liehn EAM, Graf JM, et al. Statin treatment after onset of sepsis in a murine model improves survival [Article]. Circulation (2005) 112:117–24.
85 Merx MWM, Liehn EAM, Janssens UM, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis [Report]. Circulation (2004) 109:2560–5.
86 Moon JC, Bogle RG. Switching statins. Br Med J (2006) 332:1344–5.
87 Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol (2001) 77:247–53.[CrossRef][Web of Science][Medline]
88 Mutunga M, Fulton B, Bullock R, et al. Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med (2001) 163:195–200.
89 Niessner A, Steiner S, Speidl WS, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis (2006) 189:408–13.[CrossRef][Web of Science][Medline]
90 Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol (1995) 15:247–51.
91 Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Crit Care (2006) 10:113.[CrossRef][Medline]
92 Novotny AR, Emmanuel K, Maier S, et al. Cytochrome P450 activity mirrors nitric oxide levels in postoperative sepsis: predictive indicators of lethal outcome. Surgery (2007) 141:376–84.[CrossRef][Web of Science][Medline]
93 Padkin AM, Goldfrad CM, Brady ARM, Young DD, Black NM, Rowan KD. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland [Article]. Crit Care Med (2003) 31:2332–8.[CrossRef][Web of Science][Medline]
94 Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol (1990) 30:1128–35.[Abstract]
95 Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation (2002) 106:1024–8.
96 Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf (1996) 14:11–24.[Web of Science][Medline]
97 Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin–gemfibrozil combination therapy. JAMA (1990) 264:71–5.
98 Pleiner JM, Schaller GM, Mittermayer FM, et al. Simvastatin prevents vascular hyporeactivity during inflammation [Article]. Circulation (2004) 110:3349–54.
99 Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 106:2104–10.
100 Remick DG. Pathophysiology of sepsis. Am J Pathol (2007) 170:1435–44.
101 Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 344:1959–65.
102 Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation (2001) 103:1191–3.
103 Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 100:230–5.
104 Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med (2001) 345:1368–77.
105 Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest (2000) 80:1095–100.[Web of Science][Medline]
106 Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther (2003) 1:495–505.[CrossRef][Medline]
107 Sabroe I, Parker LC, Dockrell DH, Davies DE, Dower SK, Whyte MK. Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 175:306–11.
108 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol (2005) 19:117–25.[CrossRef][Web of Science][Medline]
109 Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy (2007) 27:325–32.[CrossRef][Web of Science][Medline]
110 Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis (2003) 14:575–85.[CrossRef][Web of Science][Medline]
111 Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther (2006) 112:71–105.[CrossRef][Web of Science][Medline]
112 Steiner SM, Speidl WSM, Pleiner JM, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo [Article]. Circulation (2005) 111:1841–6.
113 Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis (2006) 6:242–8.[CrossRef][Web of Science][Medline]
114 Terkeltaub R, Solan J, Barry M Jr, Santoro D, Bokoch GM. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol (1994) 55:749–55.[Abstract]
115 Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med (2001) 164:1601–5.
116 Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol (1992) 32:630–8.[Abstract]
117 Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 16:379–414.
118 van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin therapy and reduced risk of pneumonia in patients with diabetes. Thorax (2006).
119 Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med (2001) 345:1359–67.
120 Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation (2004) 110:886–92.
121 Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol (2000) 35:1–10.
122 Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells [Review]. Coron Artery Dis (2004) 15:235–42.[CrossRef][Web of Science][Medline]
123 Warnholtz AM, Genth-Zotz SM, Munzel TM. Should treatment of sepsis include statins? [Editorial]. Circulation (2005) 111:1735–7.
124 Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol (1997) 30:1212–7.[Abstract]
125 Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med (2001) 7:687–92.[CrossRef][Web of Science][Medline]
126 Winning J, Claus RA, Huse K, Bauer M. Molecular biology on the ICU. From understanding to treating sepsis. Minerva Anestesiol (2006) 72:255–67.[Web of Science][Medline]
127 Yamada Y, Endo S, Kasai T, et al. Nuclear matrix protein, tumor necrosis factor-alpha, and nitrite/nitrate levels in patients with multiple organ dysfunction syndrome. Res Commun Mol Pathol Pharmacol (1998) 100:92–104.[Web of Science][Medline]
128 Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int (2006) 69:1535–42.[CrossRef][Web of Science][Medline]
129 Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol (2001) 21:1165–71.
130 Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb (2006) 13:108–13.[Web of Science][Medline]
131 Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of enos and oxidant stress [Article]. Hypertension (2004) 44:186–90.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. M. Tleyjeh, T. Kashour, F. A. Hakim, V. A. Zimmerman, P. J. Erwin, A. J. Sutton, and T. Ibrahim Statins for the Prevention and Treatment of Infections: A Systematic Review and Meta-analysis Arch Intern Med, October 12, 2009; 169(18): 1658 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Prinz and M. Endres The Acute (Cerebro)Vascular Effects of Statins Anesth. Analg., August 1, 2009; 109(2): 572 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. L. S. Brookes, C. C. McGown, and C. S. Reilly Statins for all: the new premed? Br. J. Anaesth., July 1, 2009; 103(1): 99 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Kruger and (on behalf of The STATInS Investigators) Statins and sepsis Br. J. Anaesth., June 1, 2008; 100(6): 862 - 862. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Randomised Trials for Statins in sepsis
- Peter S Kruger, et al.
- British Journal of Anaesthesia, 9 Mar 2008 [Full text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||